Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5.
EDOXABAN vs HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin sodium binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa), thereby inhibiting coagulation.
60 mg orally once daily
Initial IV bolus of 5000 units, followed by continuous IV infusion at 1300 units/hour (typically 25,000 units in 500 mL D5W at 26 mL/hour) for therapeutic anticoagulation; dose titrated to aPTT 1.5-2.5 times control.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Terminal elimination half-life is approximately 1.5 hours (range 1–2 hours) after intravenous administration; dose-dependent: at therapeutic doses, half-life is about 1 hour; at higher doses, up to 2.5 hours. Clinical context: shorter half-life in pulmonary embolism, longer in renal impairment.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Renal: negligible; primarily metabolized by the liver and reticuloendothelial system; small amount excreted unchanged in urine (<5%). Biliary/fecal: minimal.
Category C
Category A/B
Anticoagulant
Anticoagulant